{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:28Z","timestamp":1793106328839,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bmc.2024.117792","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:48:31Z","timestamp":1718228911000},"page":"117792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Enhancing anti-cancer capacity: Novel class I\/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-0726","authenticated-orcid":false,"given":"Hsueh-Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Hsien","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Chieh","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117792_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-Cancer J Clin"},{"key":"10.1016\/j.bmc.2024.117792_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1471-2407-10-329","article-title":"Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells","volume":"10","author":"Henriksen","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bmc.2024.117792_b0015","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer Progress and Priorities: Lung Cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol, Biomark Prevent : Publ Am Associat Cancer Res, Cosponsored Am Soc Prevent Oncol"},{"key":"10.1016\/j.bmc.2024.117792_b0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-Cancer J Clin"},{"key":"10.1016\/j.bmc.2024.117792_b0025","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3892\/or.2015.3879","article-title":"HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells","volume":"33","author":"Ji","year":"2015","journal-title":"Oncology Reports"},{"key":"10.1016\/j.bmc.2024.117792_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117792_b0035","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Investigat"},{"key":"10.1016\/j.bmc.2024.117792_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020148","article-title":"Histone deacetylase inhibitors and phenotypical transformation of cancer cells","volume":"11","author":"Wawruszak","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2024.117792_b0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2017.11.010","article-title":"E-cadherin: Its dysregulation in carcinogenesis and clinical implications","volume":"121","author":"Wong","year":"2018","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.bmc.2024.117792_b0050","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1101\/gad.9.10.1149","article-title":"Inhibitors of mammalian G1 cyclin-dependent kinases","volume":"9","author":"Sherr","year":"1995","journal-title":"Genes Devel"},{"key":"10.1016\/j.bmc.2024.117792_b0055","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1006\/excr.1998.4319","article-title":"Transcriptional regulation of the p21((WAF1\/CIP1)) gene","volume":"246","author":"Gartel","year":"1999","journal-title":"Experiment Cell Res"},{"key":"10.1016\/j.bmc.2024.117792_b0060","first-page":"164","article-title":"p53-independent induction of p21 (WAF1\/CIP1), reduction of cyclin B1 and G2\/M arrest by the isoflavone genistein in human prostate carcinoma cells, Japanese journal of cancer research","volume":"91","author":"Choi","year":"2000","journal-title":"Gann"},{"key":"10.1016\/j.bmc.2024.117792_b0065","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","article-title":"Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites","volume":"19","author":"Huang","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117792_b0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.18632\/oncotarget.23070","article-title":"HDAC inhibitor PAC-320 induces G2\/M cell cycle arrest and apoptosis in human prostate cancer","volume":"9","author":"Dong","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2024.117792_b0075","first-page":"384","article-title":"The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways","volume":"28","author":"Meng","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bmc.2024.117792_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-010-1310-4","article-title":"CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status","volume":"130","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treatment"},{"key":"10.1016\/j.bmc.2024.117792_b0085","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7150\/jca.34091","article-title":"Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells","volume":"11","author":"Liao","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.bmc.2024.117792_b0090","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.sjbs.2015.03.005","article-title":"Regulation of ceramide channel formation and disassembly: Insights on the initiation of apoptosis","volume":"22","author":"Abou-Ghali","year":"2015","journal-title":"Saudi J Biol Sci"},{"key":"10.1016\/j.bmc.2024.117792_b0095","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117792_b0100","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117792_b0105","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.3390\/v4123831","article-title":"Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy","volume":"4","author":"Yuan","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2024.117792_b0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Experiment Mol Med"},{"key":"10.1016\/j.bmc.2024.117792_b0115","first-page":"299","article-title":"Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises","volume":"14","author":"Garmpis","year":"2017","journal-title":"Can Gen pro"},{"key":"10.1016\/j.bmc.2024.117792_b0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3727\/000000001783992687","article-title":"Role of histone acetylation in the assembly and modulation of chromatin structures","volume":"9","author":"Annunziato","year":"2000","journal-title":"Gene Expression"},{"key":"10.1016\/j.bmc.2024.117792_b0125","first-page":"37","article-title":"Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect?","volume":"38","author":"Damaskos","year":"2018","journal-title":"Anticancer Research"},{"key":"10.1016\/j.bmc.2024.117792_b0130","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117792_b0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin Therap Patents"},{"key":"10.1016\/j.bmc.2024.117792_b0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J Cancer Res Therap"},{"key":"10.1016\/j.bmc.2024.117792_b0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bmc.2024.117792_b0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2013.12.016","article-title":"A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies","volume":"346","author":"Huang","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2024.117792_b0160","doi-asserted-by":"crossref","first-page":"e30240","DOI":"10.1371\/journal.pone.0030240","article-title":"Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models","volume":"7","author":"Shieh","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bmc.2024.117792_b0165","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0b013e3283300a0f","article-title":"A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways","volume":"20","author":"Hwang","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bmc.2024.117792_b0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4161\/cc.4.5.1690","article-title":"Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin","volume":"4","author":"Robbins","year":"2005","journal-title":"Cell Cycle (Georgetown Tex.)"},{"key":"10.1016\/j.bmc.2024.117792_b0175","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s002800100322","article-title":"Histone deacetylases and transcriptional therapy with their inhibitors","volume":"48","author":"Pandolfi","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2024.117792_b0180","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117792_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.flatc.2021.100320","article-title":"Integration of PEG and PEI with graphene quantum dots to fabricate pH-responsive nanostars for colon cancer suppression in vitro and in vivo","volume":"31","author":"Lee","year":"2022","journal-title":"Flatchem"},{"key":"10.1016\/j.bmc.2024.117792_b0190","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/14756366.2021.1941920","article-title":"Ring size changes in the development of class I HDAC inhibitors","volume":"36","author":"Cho","year":"2021","journal-title":"J Enzym Inhib Med Ch"},{"key":"10.1016\/j.bmc.2024.117792_b0195","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/genes13112111","article-title":"Mitochondrial factor C20orf7 facilitates the EMT-mediated cancer cell migration and the proliferation of colon cancer in vitro and in vivo","volume":"13","author":"Liu","year":"2022","journal-title":"Genes-Basel"},{"key":"10.1016\/j.bmc.2024.117792_b0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbrc.2021.06.034","article-title":"Multiple myeloma driving factor WHSC1 is a transcription target of oncogene HMGA2 that facilitates colon cancer proliferation and metastasis","volume":"567","author":"Liu","year":"2021","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.bmc.2024.117792_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109778","article-title":"A novel HDAC1\/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation","volume":"352","author":"Lee","year":"2022","journal-title":"Chem-Biol Interact"},{"key":"10.1016\/j.bmc.2024.117792_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jece.2023.110762","article-title":"MOF-derived spinel NiMn2O4\/CoMn2O4 heterojunction and its application in a high-performance photocatalyst and supercapacitor","volume":"11","author":"Lee","year":"2023","journal-title":"J Environ Chem Eng"},{"key":"10.1016\/j.bmc.2024.117792_b0215","doi-asserted-by":"crossref","first-page":"e43645","DOI":"10.1371\/journal.pone.0043645","article-title":"Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One1"},{"key":"10.1016\/j.bmc.2024.117792_b0220","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/jm401899x","article-title":"Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells","volume":"57","author":"Lee","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117792_b0225","article-title":"Tubulin Post-translational modifications: the elusive roles of acetylation","volume":"12","author":"Carmona","year":"2023","journal-title":"Biology-Basel"},{"key":"10.1016\/j.bmc.2024.117792_b0230","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bmc.2024.117792_b0235","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ncb1903","article-title":"Histone levels are regulated by phosphorylation and ubiquitylation-dependent proteolysis","volume":"11","author":"Singh","year":"2009","journal-title":"Nat Cell Biol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T20:39:35Z","timestamp":1728160775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624002062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S0968089624002062"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117792","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing anti-cancer capacity: Novel class I\/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117792"}}